Growth Metrics

Novartis Ag (NVS) Cash from Operations Growth (3y) (2020 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 45.52%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -8.27%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -2.98%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 43.03%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.18%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 13.41%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 29.22%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -28.10%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 21.07%
Dec 31, 2024 4.47%
Jun 30, 2024 5.67%
Dec 31, 2023 0.23%
Jun 30, 2023 -3.35%
Jun 30, 2022 6.47%
Jun 30, 2021 1.58%
Jun 30, 2020 3.41%